X

Trial Profile

A phase 1b study of OT-101 in combination of IL-2

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aldesleukin (Primary) ; Trabedersen (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

20 Oct 2021 According to an Oncotelic Therapeutics media release, this study is scheduled to complete in 2020.
15 Mar 2021 Status changed from planning to recruiting, according to a Mateon Therapeutics media release.
15 Mar 2021 According to a Mateon Therapeutics media release, the trial will confirm the safety and effectiveness of OT-101/IL-2 in solid cancer patients in cooperation with the UK global pharmaceutical company Clinigen Group. The study will be conducted together with Autotelic BIO- a partner of Mateon on OT-101/IL-2 combination.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com